(SANTA CLARA, CALIF., JAN. 13, 2015) — CROWN BIOSCIENCE, A GLOBAL DRUG DISCOVERY AND DEVELOPMENT SERVICES COMPANY PROVIDING TRANSLATIONAL PLATFORMS TO ADVANCE ONCOLOGY AND METABOLIC DISEASE RESEARCH, HAS ANNOUNCED THE APPOINTMENT OF ERIC MURPHY, PH.D., AS GLOBAL SCIENTIFIC DIRECTOR FOR TRANSLATIONAL ONCOLOGY.
“For more than 20 years, Dr. Murphy has focused on translational and drug discovery research for some of the most respected academic and biopharmaceutical organizations in the world,” said Laurie Heilmann, senior vice president of global strategy, marketing and business development at Crown Bioscience. “Working with our innovative research and development teams to leverage our scientific platforms, he will assist clients with early preclinical studies and support clinical development strategies to translate new cancer therapeutics.”
Most recently, Murphy designed and implemented a world-class screening operation for a biotechnology company focused on regenerative medicine. This led to phenotypic screening and compound profiling to support both discovery and translational research programs. The unit also performed translational research for clinical programs for cancer, osteoarthritis and alopecia.
Working for a large global pharmaceutical company, Murphy employed numerous in vivoefficacy studies to identify new targets and in vitro high throughput phenotypic screens to identify new chemical starting points while building an extensive network of academic collaborations to perform translational and drug discovery research.
Murphy’s academic research included the design of advanced gene delivery systems for cancer therapy in syngeneic models. He earned his Ph.D. from the University of California – Irvine and performed a post-doctoral fellowship with a research focus on angiogenesis, cancer biology, nanomedicine and drug discovery at the Moores Cancer Center at the University of California San Diego.
“Adding this position in translational oncology demonstrates CrownBio’s commitment to assisting clients from in vitro research in the earliest preclinical stages through the translational stage to usher research programs into the clinical setting,” Heilmann said.
To learn more about Crown Bioscience’s innovative translational oncology platforms, visit www.crownbio.com.